Day One Biopharmaceuticals Inks $60M
SOUTH SAN FRANCISCO, CA, Day One Biopharmaceuticals has raised $60 million in a Series A funding.
Using new insights from the biology of pediatric cancer, Day One Biopharmaceuticals develops promising new oncology therapies that change outcomes for people of all ages. Today, Day One unveils its team, $60M Series A financing, and announces its first promising clinical-stage oncology treatment, which Day One acquired through Takeda Pharmaceutical Company Limited.
Advances in cancer research enable drug developers to identify children and adults who may benefit from the same medicine. Yet, children with cancer continue to be left behind. "In the US, children with cancer first gain access to cutting-edge investigational treatments an average of 6.5 years later than adults. This disparity in access occurs for multiple reasons, including the prioritization of adult cancers that can create larger markets; a development model that remains centered on adult conditions versus mechanism of action; and outdated assumptions around trial feasibility in pediatric oncology. As a result, only 10 new drugs for pediatric cancer have been FDA approved over the last 30 years," explained Dr. Samuel Blackman, co-founder, pediatric oncologist, and Chief Medical Officer of Day One. "Our goal is to dramatically change the pace of new cancer drug development for children by identifying and developing novel therapies based on pediatric cancer biology, and then following the biology to the benefit of all patients whether they are children or adults."
Enabled by advances in the understanding of the biology of childhood cancers, and informed by its network of leading pediatric oncologists, Day One is equipped to identify patients across the age spectrum who are likely to benefit from a new treatment based upon their tumor's biology. In parallel, Day One leverages improvements in pediatric oncology clinical trial infrastructure and modern study designs to execute faster and more efficient clinical trials for children with cancer. "This confluence allows new targeted therapies to be developed for both childhood and adult cancers with equal speed and intensity. A small focused company, like Day One, can execute rapidly to deliver new treatments for people with cancer. I am delighted to back Day One on this mission, " Dr. Daniel Becker, Principal at Access Biotechnology.
Day One was incubated at Canaan through a focused effort to identify, acquire, and develop promising new treatments that could address childhood cancers. "Cancer impacts patients of all ages. New treatments should, too," noted Julie Grant, acting-CEO at Day One and General Partner at Canaan. "At Day One we ask - what is the fastest path to FDA approval and insurance coverage for this product? Treating patients whose tumors are most likely to respond to treatment, irrespective of age, as quickly as possible is a simple and often underutilized strategy. Our team is focused on development innovation and rapid execution, in addition to being at the forefront of cancer biology."
To execute on its strategy, Day One recruited a deeply experienced and creative team of drug developers to urgently pursue innovative clinical trials for children and adults with cancer. Details about Day One's team can be found here. Day One's extended community of supporters also includes leading physician-scientists and clinical investigators who help inform Day One's translational and clinical plans, and members of the patient/parent advocacy community who ensure patient-centricity and a focus on the greatest unmet needs. "It is clear that Day One was purpose-built to serve the mission of accelerating pediatric oncology drug development," notes Dr. Daphne Haas-Kogan, Chair of the Department of Radiation Oncology at the Dana-Farber Cancer Institute, who treats both children and adults with cancer. "The depth and experience of their team, their deep commitment to the needs of these patients and their families, and their willingness to include families, investigators, and regulators from the start are unparalleled."
Day One also announced today that it acquired Takeda's rights to develop and commercialize DAY101 (formerly TAK-580) worldwide, including certain rights previously licensed by Takeda from Sunesis Pharmaceuticals. In parallel, Day One re-negotiated with Sunesis the terms of the licensing agreement acquired from Takeda. Takeda retains license to develop and commercialize DAY101 in certain rare disease indications.
"With its strong expertise in pediatric oncology, Day One is the ideal partner to continue advancing DAY101, which may one day provide a new treatment option for children with relapsed gliomas," said Chris Arendt, PhD, Head of Takeda's Oncology Therapeutic Area Unit.
DAY101 is a potent selective oral, once-a-week, small molecule type II inhibitor of RAF, an oncogenic driver in a range of cancers including pediatric glioma and adult solid tumors. Over 250 patients have received DAY101 in clinical trials thus far. DAY101 demonstrated early clinical activity across adult and pediatric populations with specific genetic alterations in the RAS/MAP kinase pathway. Details of the clinical safety and efficacy data will be announced in 2020 and 2021.
Tumors harboring genetic alterations, such as BRAF wildtype fusions, BRAF mutations, and other alterations in the MAPK pathway could be addressed by DAY101. Many of these populations cannot be adequately treated with incumbent BRAF or MEK inhibitors. Michael Gladstone, Principal at Atlas Venture, said "Targeted oncology therapies in the RAS/MAP kinase pathway can deliver tremendous benefit to patients young and old. Our priority is developing DAY101 as both a monotherapy and in combination with complementary therapies to treat a range of aggressive cancers that are not served by existing drugs." Canaan, Access Biotechnology, and Atlas Venture jointly funded the $60M series A round to develop DAY101 and to expand the pipeline through additional partnerships.
An investigator sponsored trial of DAY101 to treat children with relapsed pediatric glioma is ongoing through the Pacific Pediatric Neuro-Oncology Consortium. The preclinical work establishing the potential of DAY101 in pediatric glioma was performed by grants from a range of philanthropic organizations including the PLGA Fund at PBTF, the Team Jack Foundation, Team Nathan and Takeda.
About DAY ONE Biopharmaceuticals
Inspired by children with cancer, Day One Biopharmaceuticals creatively and intentionally develops promising new therapies that change the outcome for people of all ages living with cancer. Day One's first announced program is DAY101, an oral, once-a-week, type II pan-RAF inhibitor that is currently being evaluated in human clinical trials. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop emerging cancer treatments that can help both children and adults living with cancer. Through Day One and its collaborators, cancer drug development comes of age. For more information, please visit www.dayonebio.net
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and hundreds of exits to date, we partner with entrepreneurs building the next generation of technology and healthcare companies that will transform how we live, work and thrive. To learn more about our people and our portfolio, please visit canaan.com
About ACCESS BIOTECHNOLOGY
Access Biotechnology is the life science investment arm of Access Industries. The investment strategy is broad, long term and aims to enable truly innovative therapeutic platforms and products across three key stages: company foundation, technology translation and company expansion. Our approach is based on rigorous diligence and we provide value-added support from our extensive experience and networks. To learn more, please visit www.accessbio-tech.com
About ATLAS VENTURE
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com
Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including its oral non-covalent BTK inhibitor vecabrutinib and first-in-class PDK1 inhibitor SNS-510. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies. For additional information on Sunesis, please visit www.sunesis.com.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about